



– **CONVENIENCE TRANSLATION** –

Data protection information for shareholders and their proxies

**for the (virtual) Annual General Meeting 2024
of**

**SCHOTT Pharma AG & Co. KGaA
Mainz**

ISIN: DE000A3ENQ51 // WKN: A3ENQ5

SCHOTT Pharma AG & Co. KGaA will process personal data of shareholders and their proxies in connection with the virtual Annual General Meeting.

You will find below information on the party responsible under data protection law (“controller”) and the data protection officer (1.). We also provide you below with the information regarding the processing of personal data (2.) and the rights of data subjects in connection with this processing (3.).

1. Controller and data protection officer

1.1. Controller

SCHOTT Pharma AG & Co. KGaA
Hattenbergstraße 10
55122 Mainz
Germany
Phone: +49-6131-66-0
Email: pharma@schott.com

SCHOTT Pharma AG & Co. KGaA is represented by its general partner SCHOTT Pharma Management AG, which in turn is represented by the members of its Management Board, Andreas Reisse and Dr. Almuth Steinkühler.

1.2. Data protection officer

Christoph Dahl
c/o SCHOTT Pharma AG & Co. KGaA
Hattenbergstraße 10
55122 Mainz
Germany
Email: info.datenschutz@SCHOTT.com

2. Processing of personal data

2.1. Personal data and its sources

SCHOTT Pharma AG & Co. KGaA will process the following personal data of shareholders and their proxies in connection with the virtual Annual General Meeting to enable shareholders and their proxies to exercise their shareholder rights in relation to the virtual Annual General Meeting:

- surname and first name, address, email address,
- number of shares, class of shares, type of ownership of the shares,
- the specific identifier given to the shareholder by the ultimate intermediary, account number of the securities account of the shareholder,
- the access data assigned to the shareholder for the password-protected InvestorPortal,
- the IP address from which the shareholder or the proxy uses the password-protected InvestorPortal, other log data that is generated for technical reasons when using the password-protected InvestorPortal (type and version of web browser, operating system used, volume of data transmitted, page accessed, page previously visited, date and time of access),
- the exercise of voting rights and the content of votes cast by absentee ballot,
- the tracking of the complete transmission of the virtual Annual General Meeting in video and audio,
- the content of questions asked by means of electronic communication and the content of their answers, as well as the content of statements submitted by means of electronic communication,
- the exercise of the right to speak and the right to information as well as the submission of motions and election proposals by means of video communication and the electronic possibility of lodging objections against resolutions of the Annual General Meeting,
- communication data of the shareholder to check the functionality of the video communication,
- if applicable, the surname, first name and address of the proxy appointed by the relevant shareholder, the granting of power of attorney to the proxy, including any voting instructions, and their specific identifier given by the ultimate intermediary.

To the extent that this personal data has not been provided by the shareholders or their proxies when registering for the virtual Annual General Meeting or received during the conduction of the virtual Annual General Meeting including the use of the password-protected InvestorPortal, their depository bank or their ultimate intermediary within the meaning of section 67c(3) of the German Stock Corporation Act (Aktengesetz, AktG) ("German Stock Corporation Act") will send their personal data to SCHOTT Pharma AG & Co. KGaA. The access data assigned to the shareholder for the password-protected InvestorPortal as well as the IP address from which the shareholder or the proxy uses the password-protected InvestorPortal shall be communicated to the Company by the service provider commissioned by the Company to conduct the virtual Annual General Meeting.

2.2. Purpose of processing and legal basis

SCHOTT Pharma AG & Co. KGaA will process the data of the shareholders and their proxies to the extent necessary to process the shareholder rights exercised by them in connection with the virtual Annual General Meeting. The legal basis for this processing is Article 6(1) lit. c) of the General Data Protection Regulation ("GDPR") (compliance with legal obligations) in conjunction with section 67e(1) of the German Stock Corporation Act.

SCHOTT Pharma AG & Co. KGaA will process the IP address from which the shareholder or the proxy uses the password-protected InvestorPortal, as well as other log data that is generated for technical reasons when using the password-protected InvestorPortal, to the extent necessary to provide the password-protected InvestorPortal and to ensure the security of the IT infrastructure used for this purpose. The legal basis for this processing is Article 6(1)(c) GDPR (compliance with legal obligations) in conjunction with section 67e(1) of the German Stock Corporation Act and Article 6(1)(f) GDPR (balancing of interests). The legitimate interest of SCHOTT Pharma AG & Co. KGaA is the provision of the password-protected InvestorPortal and the guarantee of the security of the IT infrastructure used for this purpose.

Furthermore, SCHOTT Pharma AG & Co. KGaA will store personal data of its shareholders and their proxies to the extent that this is necessary to comply with statutory obligations to retain data. The legal basis for this processing is Article 6(1)(c) GDPR (compliance with legal obligations) in conjunction with the respective statutory retention obligations.

Moreover, SCHOTT Pharma AG & Co. KGaA will possibly continue to store personal data of its shareholders and their proxies to the extent that this is necessary to establish, exercise or defend legal claims. The legal basis for this processing is Article 6(1)(f) GDPR (balancing of interests). SCHOTT Pharma AG & Co. KGaA's legitimate interest is to establish, exercise or defend legal claims.

2.3. How long do we keep your personal data?

SCHOTT Pharma AG & Co. KGaA will store this personal data for the purposes mentioned above only for as long as this is necessary for these purposes.

Log data that is technically generated when using the password-protected InvestorPortal is stored in so-called log files for a maximum period of 7 days, unless a security-relevant event occurs (e.g. a DDoS attack). In the event of a security-relevant event, log files are stored until the security-relevant event has been eliminated and fully clarified.

Otherwise, the storage period for the purposes mentioned above is regularly up to three years.

If a shareholder is no longer a shareholder of the Company, SCHOTT Pharma AG & Co. KGaA will only store his or her personal data for a maximum of twelve months on the basis of section 67e(2) sentence 1 of the German Stock Corporation Act and subject to other statutory provisions.

Data will only be stored for a longer period on the basis of section 67e(2) sentence 2 of the German Stock Corporation Act and subject to other statutory provisions as long as this is necessary for any possible legal proceedings to establish, exercise or defend legal claims. In this case, SCHOTT Pharma AG & Co. KGaA will store the data until the end of the respective legal proceeding.

2.4. Who else receives your personal data?

The following service provider will process the above data for the above purposes on behalf of SCHOTT Pharma AG & Co. KGaA (as “processor”):

Computershare Deutschland GmbH & Co. KG
Eisenheimerstraße 61
80687 München
Germany

The service provider will only receive personal data from SCHOTT Pharma AG & Co. KGaA that is required to perform the commissioned service and will process the data exclusively in accordance with SCHOTT Pharma AG & Co. KGaA’s instructions.

Otherwise, SCHOTT Pharma AG & Co. KGaA will only make the personal data available to shareholders and their proxies as well as to third parties in connection with the virtual Annual General Meeting within the framework of the statutory provisions. In particular, if shareholders and their proxies are to be represented at the virtual Annual General Meeting by a proxy appointed by the Company disclosing their name, SCHOTT Pharma AG & Co. KGaA will enter their names, place of residence, number of shares and type of ownership in the list of attendees of the Annual General Meeting to be drawn up in accordance with section 129(1) sentence 2 of the German Stock Corporation Act. All shareholders who are

electronically connected to the virtual Annual General Meeting and their proxies can view this data on the password-protected InvestorPortal during the virtual Annual General Meeting and shareholders may also inspect it up to two years later pursuant to section 129(4) sentence 2 of the German Stock Corporation Act. With regard to the transfer of personal data to third parties in connection with the announcement of shareholder requests for additions to the agenda, statements submitted as well as counter motions and election proposals by shareholders, please refer to the explanations in Part V.no. 5 of the invitation to the virtual Annual General Meeting on 14 March 2024.

If shareholders or their proxies make use of their right to request information pursuant to section 131(1) of the German Stock Corporation Act or otherwise speak, this might be done by stating the name and, if applicable, the place of residence or registered office of the shareholder asking the question and/or his or her proxy. Requests for information and other requests to speak can only be acknowledged by other participants in the virtual Annual General Meeting. Pursuant to section 130a(3) of the German Stock Corporation Act, comments submitted will be made available to other users of the password-protected InvestorPortal as described in Part V.no. 5 of the invitation to the virtual Annual General Meeting. In the case of requests for supplements pursuant to section 278 (3) in conjunction with section 122(2) of the German Stock Corporation Act and in the case of counter motions and election proposals pursuant to section 278 (3) in conjunction with sections 126(1), 127 of the German Stock Corporation Act, these will be made publicly accessible as explained in more detail in Part V.no. 5 of the invitation to the virtual Annual General Meeting and, if applicable, be proposed for voting in the virtual Annual General Meeting.

2.5. No transfer of personal data to third countries

SCHOTT Pharma AG & Co. KGaA will not transfer the personal data processed in the context of the virtual Annual General Meeting to countries outside the European Union or the European Economic Area (“third countries”).

2.6. No obligation to provide the data

Shareholders and their proxies are not obliged to provide SCHOTT Pharma AG & Co. KGaA with the abovementioned data in connection with the Annual General Meeting. Provision of the data is not required by law or by contract. The data is also not required for the conclusion of a contract. However, the provision of personal data is absolutely necessary to exercise shareholder rights with respect to the Annual General Meeting.

Insofar, if shareholders and their proxies do not provide the data, SCHOTT Pharma AG & Co. KGaA will not be able to enable them to exercise shareholder rights in relation to the Annual General Meeting.

2.7. No automated decision-making, including profiling

SCHOTT Pharma AG & Co. KGaA will not carry out any automated decision-making, including profiling, on the basis of the personal data pursuant to Article 22(1) and (4) GDPR.

2.8. Use of technically necessary cookies for the password-protected InvestorPortal

In order to ensure the secure operation of the password-protected InvestorPortal and to enable the use of certain functions, technically essential cookies are used. These are small text files that are stored on the end device of shareholders or their proxies when they use the InvestorPortal. When the InvestorPortal is called up again with the same terminal device, the cookie and the information stored in it can be retrieved. Shareholders and their proxies can generally prevent the use of cookies via their browser settings. However, completely blocking all cookies may mean that the password-protected InvestorPortal cannot be used under certain circumstances.

3. Rights of data subjects in relation to the processing

The shareholders and their proxies have the following rights with respect to the processing of their personal data as data subjects:

- right of access (Article 15 GDPR)
- right to rectification (Article 16 GDPR)
- right to erasure (“right to be forgotten”) (Article 17 GDPR)
- right to restriction of processing (Article 18 GDPR)
- right to data portability (Article 20 GDPR)
- right to object (Article 21 GDPR)
- right to withdraw consent (Article 7(3) GDPR)

The following right to object under Article 21(1) GDPR is especially highlighted:

Right to object on grounds relating to the data subject’s particular situation (Article 21(1) GDPR)

Shareholders and their proxies have the right as data subjects pursuant to Article 21(1) GDPR to object, on grounds relating to their particular situation, at any time to processing of personal data concerning them which is based on Article 6(1) lit. f) GDPR (see clause 2.2.).

If an objection is raised, SCHOTT Pharma AG & Co. KGaA will no longer process the personal data unless SCHOTT Pharma AG & Co. KGaA demonstrates compelling legitimate grounds for the processing which override the interests, rights and freedoms of the shareholders and their proxies as data subjects, or the processing serves the establishment, exercise or defense of legal claims.

Data subjects can contact SCHOTT Pharma AG & Co. KGaA or its data protection officer using the contact details referred to above in order to exercise their rights. In addition, shareholders and their proxies as data subjects have a right to lodge a complaint with a data protection supervisory authority (Article 77 GDPR). Data subjects can assert this right to lodge a complaint in particular to the supervisory authority of the (federal) state in which they have their domicile or habitual residence or the data protection supervisory authority of the federal state of Rhineland-Palatinate (*Landesbeauftragte für den Datenschutz und die Informationsfreiheit Rheinland-Pfalz*), where SCHOTT Pharma AG & Co. KGaA has its registered office.

For more information on the General Data Protection Regulation and the rights of data subjects in relation to the processing of their personal data, please refer to the [online information brochure \(in German only\) of the Federal Commissioner for Data Protection and Freedom of Information \(Der Bundesbeauftragte für den Datenschutz und die Informationsfreiheit, BfDI\)](#).

